Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citation
Cited by
Items 501–600 of 1,004
Li, Y., Zhou, C., Li, J. H., Luo, E., Zhu, S., Feng, G., & Hu, J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1751-6 · Cited by 71
“For the application of ZA, a 5-mg once yearly infusion through intravenous injection was reported for treatment of postmenopausal osteoporosis in clinical trials [42, 43].”
MethodYıldız, A., Esen, E., Kürkçü, M., Damlar, İ., Dağlıoğlu, K., & Akova, T. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.07.066 · Cited by 61
Bolland, M. J., Grey, A. B., Horne, A. M., Briggs, S. E., Thomas, M. G., Ellis-Pegler, R. B., Gamble, G. D., & Reid, I. R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1424 · Cited by 61
“of iv zoledronate (2, 3) that reported prevention of osteo-”
BackgroundSelf-citationBhoopalam, N., Campbell, S. C., MORITZ, T. E., Broderick, W. R., Iyer, P., Arcenas, A. G., Veldhuizen, P. J. V., FRIEDMAN, N. C., Reda, D. J., Warren, S. R., et al. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.07.046 · Cited by 62
Medicamentos para o tratamento da osteoporose: revisão
Khajuria, D. K., Razdan, R., & Mahapatra, D. R. (2011) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042011000400008 · Cited by 137
The Bone Biologic Effects of Zoledronate in Healthy Dogs and Dogs with Malignant Osteolysis
Fan, T. M., Lorimier, L. P. D., Garrett, L. D., & Lacoste, H. (2008) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2008.0046.x · Cited by 61
Identify fracture-critical regions inside the proximal femur using statistical parametric mapping
Li, W., Kornak, J., Harris, T. B., Keyak, J. H., Li, C., Lü, Y., Cheng, X., & Lang, T. (2008) · Bone · doi:10.1016/j.bone.2008.12.008 · Cited by 61
Prevrhal, S., Krege, J. H., Chen, P., Genant, H. K., & Black, D. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902790993 · Cited by 64
Self-citationHue, T. F., Cummings, S. R., Cauley, J. A., Bauer, D. C., Ensrud, K. E., Barrett-Connor, E. L., & Black, D. M. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3634 · Cited by 66
Self-citationSchuiling, K., Robinia, K., & Nye, R. (2011) · Journal of Midwifery & Women s Health · doi:10.1111/j.1542-2011.2011.00135.x · Cited by 82
Bone anabolics in osteoporosis: Actuality and perspectives
Montagnani, A. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i3.247 · Cited by 62
Secondary prevention of osteoporotic fractures—an “OPTIMAL” model of care from Singapore
Chandran, M., Tan, M. Z.-W., Cheen, M. H. H., Tan, S., Leong, M. Q., & Lau, T. C. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2368-8 · Cited by 70
“Fractures beget fractures, and though substantial evidence exists that treating patients with previous fragility fractures can reduce subsequent fractures by up to 50 % [2, 3], only about 20 % of patients with low impact fractures are ever tested or treated for osteoporosis [4–7].”
BackgroundSims, N. A., & Ng, K. W. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0196-1 · Cited by 70
Arabmotlagh, M., Pilz, M., Warzecha, J., & Rauschmann, M. (2008) · Journal of Orthopaedic Research® · doi:10.1002/jor.20748 · Cited by 60
The evolution of selective estrogen receptor modulators in osteoporosis therapy
Hadji, P. (2012) · Climacteric · doi:10.3109/13697137.2012.688079 · Cited by 68
Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
Anastasilakis, A. D., Pοlyzos, S. A., Gkiomisi, A. I., Saridakis, Z. G., Digkas, D., Bisbinas, I., Sakellariou, G. T., Παπαθεοδώρου, Α., Kokkoris, P., & Makras, P. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3174-2 · Cited by 60
“As this was a single year study and BMD changes are likely to be more prominent in the spine than the hip, we only included LS measurements [2, 3].”
Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates
Sharma, A., Einstein, A. J., Vallakati, A., Arbab‐Zadeh, A., Walker, M. D., Mukherjee, D., Homel, P., BORER, J. S., & Lichstein, E. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.03.008 · Cited by 64
Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig, L. M. B., Lane, J., & O’Connor, M. I. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200806000-00028 · Cited by 73
Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis
Cummings, S. R., Martín, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P. D., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000363236.41902.96 · Cited by 63
Self-citationThe treatment gap: The missed opportunities for osteoporosis therapy
Fuggle, N. R., Curtis, E., Clynes, M. A., Zhang, J., Ward, K. A., Javaid, M. K., Harvey, N. C., Dennison, E. M., & Cooper, C. C. (2020) · Bone · doi:10.1016/j.bone.2020.115833 · Cited by 70
Prevention and Treatment of Postmenopausal Osteoporosis
Lewiecki, E. M. (2008) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2008.03.007 · Cited by 69
Curtis, J. R., Laster, A., Becker, D. J., Carbone, L., Gary, L. C., Kilgore, M. L., Matthews, R. S., Morrisey, M. A., Saag, K. G., Tanner, S. B., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0821-x · Cited by 59
Kemmler, W., Engelke, K., & von Stengel, S. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2608 · Cited by 35
“88) on a par with zoledronate,((44)) denosumab,((45)) or teriparatid((46)) therapy.”
BackgroundBisphosphonate Treatment for Children With Disabling Conditions
Boyce, A. M., Tosi, L. L., & Paul, S. M. (2013) · PM&R · doi:10.1016/j.pmrj.2013.10.009 · Cited by 64
“The literature pertaining to adults supports improvement in clinical outcomes with the use of bisphosphonates [2,3]; however, because of differences in pediatric skeletal metabolism, caution is required when attempting to extrapolate adult data to children.”
BackgroundLocally Delivered Bisphosphonate for Enhancement of Bone Formation and Implant Fixation
Bobyn, J., McKenzie, K., Karabasz, D., Krygier, J. J., & Tänzer, M. (2009) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.i.00518 · Cited by 61
Curtis, J. R., Arora, T., Matthews, R. S., Taylor, A. J., Becker, D. J., Colon-Emeric, C. S., Kilgore, M. L., Morrisey, M. A., Saag, K. G., Safford, M. M., et al. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2009.12.004 · Cited by 66
Are Race and Sex Associated With the Occurrence of Atypical Femoral Fractures?
Marcano, A. I., Taormina, D. P., Egol, K. A., Peck, V., & Tejwani, N. C. (2013) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-013-3352-5 · Cited by 58
Chen, L.-P., Chang, T., Huang, T., Kwok, T.-G., & Lu, Y. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9887-y · Cited by 61
Assessment and management of fracture risk in patients with Parkinson's disease
Lyell, V., Henderson, E. J., Devine, M., & Gregson, C. L. (2014) · Age and Ageing · doi:10.1093/ageing/afu122 · Cited by 58
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Berney, S. M. (2008) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)79119-3 · Cited by 58
Management of atypical femoral fracture: a scoping review and comprehensive algorithm
Toro, G., Ojeda‐Thies, C., Calabrò, G., Toro, G., Moretti, A., Guerra, G., Caba-Doussoux, P., & Iolascon, G. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1086-8 · Cited by 67
Blouin, J., Dragomir, A., Moride, Y., Ste‐Marie, L., Fernandes, J., & Perreault, S. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03178.x · Cited by 61
Wilkinson, G. S., Baillargeon, J., Kuo, Y., Freeman, J. L., & Goodwin, J. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7524 · Cited by 59
Hershman, D. L., McMahon, D. J., Crew, K. D., Shao, T. H., Cremers, S., Brafman, L., Awad, D., & Shane, E. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1366 · Cited by 57
“0 Race/ethnicity White 34 (41) 14 (52) 10 (34) Hispanic 36 (43) 10 (37) 13 (45) Black 10 (18) 3 (11) 6 (21) Asian 3 (4) 0 (0) 0 (0) Stage 1 27 (32) 9 (33) 13 (43) 2 54 (64) 17 (63) 16 (53) 3 4 (4) 1 (4) 1 (3) Hormone receptor positive 56 (66) 23 (85) 20 (67) Tamoxifen (n) 44 7 9 Aromatase inhibitor (n) 12 16 11 Chemot…”
Dimai, H. P., & Fahrleitner‐Pammer, A. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101780 · Cited by 63
Treatment Sequence for Osteoporosis
Cosman, F., Langdahl, B. L., & Leder, B. Z. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.01.014 · Cited by 69
Self-citationDíez‐Pérez, A., Adachi, J. D., Adami, S., Anderson, F. A., Boonen, S., Chapurlat, R. D., Compston, J. E., Cooper, C. C., Gehlbach, S. H., Greenspan, S. L., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2023 · Cited by 61
Self-citationSafety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
Carbonare, L. D., Zanatta, M., Gasparetto, A., & Valenti, M. T. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6285 · Cited by 62
Alghamdi, H. S., & Jansen, J. A. (2012) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2012.0400 · Cited by 65
“174,175 However, all BP drugs have basically the same chemical structure (two phosphonic acids joined to a carbon atom; P–”
Yearly Zoledronic Acid in Postmenopausal Osteoporosis
de Nijs, R. N. J., & Westgeest, A. A. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071514 · Cited by 62
Rolph, D. N., Deb, M., Kanji, S., Greene, C. J., Das, M., Joseph, M., Aggarwal, R., Leblebicioğlu, B., & Das, H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.032 · Cited by 59
Effects of bisphosphonates on osteoporosis: Focus on zoledronate
Oryan, A., & Sahvieh, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118681 · Cited by 64
van der Burgh, A. C., de Keyser, C. E., Zillikens, M. C., & Stricker, B. H. C. (2021) · Drugs · doi:10.1007/s40265-021-01625-8 · Cited by 64
Parkinson's disease: A risk factor for osteoporosis
Malochet‐Guinamand, S., Durif, F., & Thomas, T. (2015) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.03.009 · Cited by 56
Macrophage Depletion by Free Bisphosphonates and Zoledronate-Loaded Red Blood Cells
Sabatino, R., Antonelli, A., Battistelli, S., Schwendener, R. A., Magnani, M., & Rossi, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101260 · Cited by 64
“However, this exacerbates toxicity problems such as nephrotoxicity, osteonecrosis of the jaws and others already occurring at clinical doses [37–41] and makes it necessary to protect bisphosphonates until their release and intracellular accumulation in the target cells.”
BackgroundFraser, L.-A., Ioannidis, G., Adachi, J. D., Pickard, L. E., Kaiser, S., Prior, J. C., Brown, J. P., Hanley, D. A., Olszynski, W. P., Anastassiades, T., et al. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1359-2 · Cited by 67
Li, B., Chau, J. F. L., Wang, Y., & Leong, W. F. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23049 · Cited by 62
Current, new and future treatments of osteoporosis
Salari, P., Abdollahi, M. R., & Larijani, B. A. (2010) · Rheumatology International · doi:10.1007/s00296-010-1586-z · Cited by 59
“In health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial (HORIZON-PFT), a 3-year randomized double-blind trial, in postmenopausal osteoporotic/osteopenic women, once yearly zoledronic acid administration, significantly increased BMD and decreased vertebral and nonvertebral fract…”
BackgroundYates, C. J., Chauchard, M.-A., Liew, D., Bucknill, A., & Wark, J. D. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.01.003 · Cited by 55
McNabb, B., Vittinghoff, E., Schwartz, A. V., Eastell, R., Bauer, D. C., Ensrud, K. E., Rosenberg, E., Santora, A. C., Barrett-Connor, E. L., & Black, D. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1864 · Cited by 59
Self-citationKomm, B. S., Morgenstern, D., Yamamoto, L. A., & Jenkins, S. N. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1099432 · Cited by 62
“Conjunctivitis and other ocular inflammatory events occurred infrequently in bisphosphonate clinical trials.[28,33,36] A short course of corticosteroids can facilitate resolution.”
BackgroundInfluentialFirst Fracture Project: addressing the osteoporosis care gap
Vaile, J. H., Sullivan, L., Bennett, C. J., & Bleasel, J. F. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01496.x · Cited by 55
Coleman, R. E., Body, J.-J., Gralow, J. R., & Lipton, A. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.005 · Cited by 56
Greiner, S. H., Wildemann, B., Back, D. A., Alidoust, M., Schwabe, P., Haas, N., & Schmidmaier, G. (2008) · Acta Orthopaedica · doi:10.1080/17453670810016768 · Cited by 67
Risk of Serious Atrial Fibrillation and Stroke With Use of Bisphosphonates
Sharma, A., Chatterjee, S., Arbab‐Zadeh, A., Goyal, S., Lichstein, E., Ghosh, J., & Aikat, S. (2013) · CHEST Journal · doi:10.1378/chest.13-0675 · Cited by 54
Qayoom, I., Teotia, A. K., & Kumar, A. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b01327 · Cited by 57
Treatment of osteoporosis after alendronate or risedronate
Eiken, P., & Vestergaard, P. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3334-4 · Cited by 55
Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid
Silverman, S. L., Kriegman, A. G., Gonçalves, J., Kianifard, F., Carlson, T. H., & Leary, E. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1448-2 · Cited by 54
“In the HORIZON-Pivotal Fracture Trial, the proportion of patients experiencing any of the five most common post-dose symptoms decreased from 32% after the first dose to 7% after the second annual dose and to 3% after the third annual dose [1].”
BackgroundResultInfluentialBisphosphonate Therapeutics in Bone Disease: The Hard and Soft Data on Osteoclast Inhibition
Drake, M. T., & Cremers, S. C. L. M. (2010) · Molecular Interventions · doi:10.1124/mi.10.3.5 · Cited by 66
Camm, A. J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.014 · Cited by 57
Dempster, D. W., Zhou, H., Recker, R. R., Brown, J. P., Bolognese, M. A., Recknor, C. P., Kendler, D. L., Lewiecki, E. M., Hanley, D. A., Rao, S. D., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2804 · Cited by 54
“Both TPTD and ZOL are effective agents for the treatment of osteoporosis.((25,28)) Both drugs lower the risk of vertebral and nonvertebral fracture and both increase BMD.”
BackgroundImpact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality
Sambrook, P. N., Chen, J. S., Simpson, J. M., & MARCH, L. M. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03835.x · Cited by 55
Pérez‐Castrillón, J. L., Pinacho, F., de Luis, D. A., López-Menéndez, M., & Dueñas‐Laita, A. (2010) · Journal of Osteoporosis · doi:10.4061/2010/401581 · Cited by 54
Management of osteoporosis in patients hospitalized for hip fractures
Ip, T., Leung, J., & Kung, A. W. C. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1398-8 · Cited by 62
“reduction in the incidence of morphometric vertebral fracture, a 25% reduction in non-vertebral fracture, and a 41% reduction in hip fracture at 36 months [62].”
BackgroundRi, M.-H., Jang, Y.-M., Ri, U.-S., Yu, C., Kim, K.-I., & Kim, S.-U. (2017) · Journal of Materials Science · doi:10.1007/s10853-017-1880-1 · Cited by 53
“The mineral binding affinity may also affect the appropriate dosing interval and the persistence of effect after discontinuation of medication [23, 24].”
BackgroundPazianas, M., Blumentals, W. A., & Miller, P. D. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0502-1 · Cited by 58
“Furthermore, in the recently published Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial, in which patients received 5 mg IV zoledronic acid once yearly, investigators reported only 1 case of ONJ in the treated group and 1 case in the placebo group after 3 years of…”
BackgroundHow zoledronic acid improves osteoporosis by acting on osteoclasts
Wang, B., Zhan, Y., Yan, L. W., & Hao, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.961941 · Cited by 60
“selectively suppress osteoclastic bone resorption through effectively inhibiting farnesyl pyrophosphate synthase (FPPS) activity in the mevalonate pathway (Black et al., 2007; Rogers et al., 2020).”
BackgroundPredictors of Fracture While on Treatment With Oral Bisphosphonates: A Population-Based Cohort Study
Prieto‐Alhambra, D., Pagès-Castellà, A., Wallace, G., Javaid, M. K., Judge, A., Nogués, X., Arden, N., Cooper, C. C., & Díez‐Pérez, A. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2011 · Cited by 57
“We used data from computerized primary care medical records linked to pharmacy invoice data for >80% of the population of Catalonia (North‐East Spain) to identify key predictors of fracture while on treatment in: (1) a population‐ based cohort of all incident users of oral BP users who started therapy in the years 200…”
Efficacy and safety of currently marketed anti-osteoporosis medications
Reginster, J., Neuprez, A., Dardenne, N., Beaudart, C., Emonts, P., & Bruyère, O. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.003 · Cited by 63
Inverse Association Between Obesity and Antinuclear Antibodies in Women
González, D. A., de León, A. C., Pérez, M. D. C. R., FUENTES, R. C., Jaime, A. A., Coello, S. D., Hernández, A. G., & Díaz, B. B. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080322 · Cited by 52
Anastasilakis, A. D., Polyzos, S. A., Gkiomisi, A., Bisbinas, I., Gerou, S., & Makras, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1402 · Cited by 52
“An a priori power analysis was performed before the recruitment of the first patient (ANOVA repeated-measures, within and between interactions for 2 time points of 2 groups [2 2]).”
MethodAnti-resorptives in the management of osteoporosis
Miller, P. D. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.004 · Cited by 56
Influence of geometry on proximal femoral shaft strains: Implications for atypical femoral fracture
Haider, I. T., Schneider, P., Michalski, A. S., & Edwards, W. B. (2018) · Bone · doi:10.1016/j.bone.2018.02.015 · Cited by 55
Naylor, K. E., Bradburn, M. J., Paggiosi, M., Gossiel, F., Peel, N. F. A., McCloskey, E. V., Walsh, J., & Eastell, R. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4460-6 · Cited by 54
Self-citationPrince, R. L., Lewis, J. R., Lim, W. H., Wong, G., Wilson, K. E., Khoo, B. C. C., Zhu, K., Kiel, D. P., & Schousboe, J. T. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3595 · Cited by 54
Kendler, D. L., Compston, J. E., CAREY, J. J., Wu, C., Ibrahim, A., & Lewiecki, E. M. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.07.010 · Cited by 58
Nanes, M. S., & Kallen, C. B. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.06.006 · Cited by 64
Tai, T.-W., Chen, C.-Y., Su, F.-C., Tu, Y.-K., Tsai, T.-T., Lin, C.-F., & Jou, I.-M. (2017) · Scientific Reports · doi:10.1038/srep44245 · Cited by 51
For the first fracture to be the last
Stolnicki, B., & Oliveira, L. G. (2016) · Revista Brasileira de Ortopedia (English Edition) · doi:10.1016/j.rboe.2016.01.005 · Cited by 62
Habib, H. A., Gil‐Hernández, B., Abu-Shandi, K. H., Sanchiz, J., & Janiak, C. (2010) · Polyhedron · doi:10.1016/j.poly.2010.05.025 · Cited by 51
Review of osteoporosis pharmacotherapy for geriatric patients
Gates, B. J., Sonnett, T. E., DuVall, C. A. K., & Dobbins, E. K. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.12.004 · Cited by 56
Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial
Grey, A., Bolland, M., Wong, S., Horne, A., Gamble, G., & Reid, I. R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2081 · Cited by 51
“J Clin Endocrinol Metab, January 2012, 97(1):286–292 jcem.”
BackgroundInfluentialSelf-citationBarrett-Connor, E. L., Swern, A. S., Hustad, C. M., Bone, H., Liberman, U. A., Papapoulos, S. E., Wang, H., de Papp, A., & Santora, A. C. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1546-9 · Cited by 50
“[4] and Cummings and colleagues [5] have reported no association, including in a second trial of intravenous zolendronate [6–11].”
BackgroundSirisoontorn, I., Hotokezaka, H., Hashimoto, M., Gonzales, C., Luppanapornlarp, S., Darendeliler, M. A., & Yoshida, N. (2012) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2011.11.016 · Cited by 53
“Zoledronic acid is a potent and novel bisphosphonate that has been recently shown to significantly reduce the risk of fractures in patients who receive the once-yearly dosing regimen for the treatment of postmenopausal osteoporosis.(14) According to several studies, zoledronic acid could be considered the most potent…”
BackgroundShould we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?
Bolland, M. J., Grey, A. B., & Reid, I. R. (2015) · Climacteric · doi:10.3109/13697137.2015.1098266 · Cited by 57
Self-citationOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club
Gielen, E., Bergmann, P., Bruyère, O., Cavalier, E., Delanaye, P., Goemaere, S., Kaufman, J., Locquet, M., Reginster, J., Rozenberg, S., et al. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0266-3 · Cited by 58
Utility of DXA for monitoring, technical aspects of DXA BMD measurement and precision testing
CAREY, J. J., & Delaney, M. F. (2017) · Bone · doi:10.1016/j.bone.2017.05.021 · Cited by 59
Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
Mignot, M.-A., Taisne, N., Legroux, I., Cortet, B., & Paccou, J. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4215-9 · Cited by 54
Liu, G., Wang, Z., Liu, L., Zhang, B., Miao, Y., & Yu, S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26550 · Cited by 57
Cancer Treatment–Related Bone Loss: A Review and Synthesis of the Literature
Khan, M. N., & Khan, A. A. (2008) · Current Oncology · doi:10.3747/co.2008.174 · Cited by 53
“PTH—Teriparatide and Full-Length PTH: Teriparatide, a 34-amino acid recombinant fragment of the 84– amino acid human PTH, is administered subcutaneously in doses of 20 µg daily for 18 months.”
BackgroundMethodInfluentialYan, T., Yin, W., Zhou, Q., Zhou, L., Jiang, Y., Du, Y., Shao, Z., & Lu, J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.021 · Cited by 50
Patel, D. V., Bolland, M. J., Nisa, Z. U., Al‐Abuwsi, F., Singh, M., Horne, A. M., Reid, I. R., & McGhee, C. N. J. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2872-5 · Cited by 52
Self-citationRANKL in the osteolysis of AES total ankle replacement implants
Koivu, H., Mackiewicz, Z., Takakubo, Y., Trokovic, N., Pajarinen, J., & Konttinen, Y. T. (2012) · Bone · doi:10.1016/j.bone.2012.05.007 · Cited by 50
Bisphosphonates in the treatment of osteoporosis
Poole, K. E. S., & Compston, J. E. (2012) · BMJ · doi:10.1136/bmj.e3211 · Cited by 56
Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: A cause for concern?
Yoon, R. S., Hwang, J., & Beebe, K. S. (2011) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.93b10.26924 · Cited by 53
de Molon, R. S., Hsu, C., Bezouglaia, O., Dry, S., Pirih, F. Q. M., Soundia, A., Cunha, F. Q., Cirelli, J. A., Aghaloo, T. L., & Tetradis, S. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2827 · Cited by 58
Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-Analysis
Albert, S. G., & Reddy, S. (2017) · Endocrine Practice · doi:10.4158/ep161678.ra · Cited by 56
Screening for Atypical Femur Fractures Using Extended Femur Scans by DXA
van de Laarschot, D. M., Smits, A. A. A., Buitendijk, S. K. C., Stegenga, M. T., & Zillikens, M. C. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3164 · Cited by 52
“Since the introduction of bisphosphonates in clinical practice two decades ago, there have been reports of several serious adverse events possibly related to the use of bisphosphonates such as osteonecrosis of the jaw,((8)) atrial fibrillation,((9)) and atypical femur fractures (AFFs).”
BackgroundBone Physiology, Disease and Treatment: Towards Disease System Analysis in Osteoporosis
Post, T. M., Cremers, S. C. L. M., Kerbusch, T., & Danhof, M. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318150-000000000-00000 · Cited by 74
Sieber, P., Lardelli, P., Kraenzlin, C. A., Kraenzlin, M. E., & Meier, C. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-012-0041-1 · Cited by 49
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.